23:49 , Oct 22, 2018 |  BC Extra  |  Clinical News

Roche reports responses for IL-2 variant at ESMO

A targeted IL-2 variant from Roche (SIX:ROG; OTCQX:RHHBY) showed monotherapy activity in patients with metastatic solid tumors in a Phase I trial. Data presented Sunday at the European Society for Medical Oncology in Munich from...
22:46 , Oct 22, 2018 |  BC Extra  |  Clinical News

Adaptimmune reports zero responses across three T cell therapy trials

Adaptimmune Therapeutics plc (NASDAQ:ADAP) fell $3.21 (30%) to $7.55 on Monday after reporting that zero of 17 evaluable patients achieved a response across the first two dose cohorts of three Phase I trials evaluating the...
18:27 , Oct 19, 2018 |  BC Week In Review  |  Company News

Roche culls pipeline, cuts include in-licensed, acquired programs

Roche (SIX:ROG; OTCQX:RHHBY) announced in its 3Q18 earnings it discontinued development of five new molecular entities, including Phase II rheumatoid arthritis candidate RG6125 (SDP051), plus two programs in development for follow-on indications. The pharma lost...
21:29 , Oct 17, 2018 |  BC Extra  |  Company News

Roche culls pipeline, cuts include in-licensed, acquired programs

Roche (SIX:ROG; OTCQX:RHHBY) announced in its 3Q18 earnings it discontinued development of five new molecular entities, including Phase II rheumatoid arthritis candidate RG6125 (SDP051), plus two programs in development for follow-on indications. The pharma lost...
18:17 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Clinical holds for Affimed's T cell bispecific following patient death

Affimed N.V. (NASDAQ:AFMD) fell $1.13 (24%) to $3.50 Oct. 9 after it placed a clinical hold on two studies of blood cancer candidate AFM11 following three treatment-related serious adverse events, including a patient death. The...
22:57 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer; infectious disease

INDICATION: Brain cancer; colorectal cancer; viral infection Mouse studies suggest inhibiting HPK1 kinase activity alone or in combination with PD-L1 inhibitors could help treat brain cancer, colorectal cancer and lymphocytic choriomeningitis virus (LCMV) infection. In...
22:23 , Oct 11, 2018 |  BC Innovations  |  Translation in Brief

Cancer antigens from RNA edits

A team from Immatics Biotechnologies GmbH and University of Texas MD Anderson Cancer Center has shown that cancer antigens generated via post-transcriptional RNA editing could further broaden the target space for immunotherapies. The study ,...
20:30 , Oct 9, 2018 |  BC Extra  |  Clinical News

Affimed sinks after placing clinical hold on bispecific T cell engager

Affimed N.V. (NASDAQ:AFMD) fell $1.13 (24%) to $3.50 Tuesday after it placed a clinical hold on two studies of blood cancer candidate AFM11 following three treatment-related serious adverse events, including a patient death. The product...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
19:46 , Oct 5, 2018 |  BC Week In Review  |  Company News

Nektar falls on short seller report

Nektar Therapeutics Inc. (NASDAQ:NKTR) fell $4.31 to $56.65 on Oct. 1 after short seller Plainview LLC released a report calling the value of the biotech's NKTR-214 zero. Nektar lost more than $740 million in market...